Stokes Capital Advisors LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 28,292 shares of the company's stock, valued at approximately $4,658,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Zone Wealth Advisors LLC boosted its stake in Zoetis by 15.2% in the 1st quarter. Blue Zone Wealth Advisors LLC now owns 29,980 shares of the company's stock valued at $4,936,000 after purchasing an additional 3,948 shares during the period. Pines Wealth Management LLC boosted its stake in Zoetis by 10.6% in the 1st quarter. Pines Wealth Management LLC now owns 2,601 shares of the company's stock valued at $428,000 after purchasing an additional 249 shares during the period. IAM Advisory LLC boosted its stake in Zoetis by 0.8% in the 1st quarter. IAM Advisory LLC now owns 10,102 shares of the company's stock valued at $1,663,000 after purchasing an additional 80 shares during the period. Intellectus Partners LLC boosted its stake in Zoetis by 19.6% in the 1st quarter. Intellectus Partners LLC now owns 6,849 shares of the company's stock valued at $1,128,000 after purchasing an additional 1,121 shares during the period. Finally, Vest Financial LLC bought a new stake in Zoetis in the 1st quarter valued at $207,000. 92.80% of the stock is currently owned by institutional investors.
Insider Activity
In other news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This represents a 2.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,188 shares of company stock valued at $367,289 over the last quarter. 0.18% of the stock is owned by company insiders.
Analyst Ratings Changes
Several research firms recently issued reports on ZTS. UBS Group reduced their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus reduced their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Piper Sandler raised their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Zoetis presently has an average rating of "Buy" and an average price target of $212.75.
Get Our Latest Stock Report on Zoetis
Zoetis Stock Up 0.9%
Shares of NYSE ZTS opened at $170.15 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market cap of $75.75 billion, a price-to-earnings ratio of 31.11, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock has a 50-day moving average price of $157.41 and a two-hundred day moving average price of $164.37.
Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.38 earnings per share. As a group, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.
Zoetis Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.18%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is currently 35.91%.
Zoetis Company Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
